European Lung Cancer Congress 2019

Oncology Meeting Resources

10 Apr - 13 Apr 2019, Geneva, Switzerland

ELCC 2019 square

The European Lung Cancer Congress 2019 is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.

Resources from European Lung Cancer Congress 2019 are available to ESMO member according to the presenters' agreement to release them. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme  | Future ESMO meetings

Watch the Expert Report Videos from ELCC 2019

Direct access to special sessions:





Format available

https://oncologypro.esmo.org/Meeting-Resour...ination-chemotherapy-in-first-line-treatment

BackgroundLung cancer has a high incidence in elderly patients. These patients are more predisposed to therapeutic toxicities, drug interactions and limitations due to physiologic alterations and comorbidities.

Date: 05 Apr 2019
Presenter: Élia Cipriano
Resources: Abstract
Topic: Geriatric Oncology

https://oncologypro.esmo.org/Meeting-Resour...eating-Fields-TTFields-on-Lung-Cancer-Models

BackgroundTumor Treating Fields (TTFields) are a clinically approved anti-mitotic treatment modality delivered via noninvasive application of low intensity, intermediate frequency, alternating electric fields.

Date: 05 Apr 2019
Presenter: Uri Weinberg
Resources: Abstract
Topics: Immunotherapy, Thoracic Malignancies

https://oncologypro.esmo.org/Meeting-Resour...-resectable-non-small-cell-lung-cancer-NSCLC

BackgroundComplex network of chemokines is a part of immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is not clear whether the concentrations of chemokines at the...

Date: 05 Apr 2019
Presenter: Marie Drosslerová
Resources: Abstract
Topic: Pathology/Molecular Biology

https://oncologypro.esmo.org/Meeting-Resour...in-metastatic-lung-cancer-in-the-Netherlands

BackgroundAdequate and timely testing for molecular alterations in NSCLC is necessary to enable treatment with tyrosine kinase inhibitors (TKI) when a certain mutation or rearrangement is present.

Date: 05 Apr 2019
Presenter: Chantal Epskamp-Kuijpers
Resources: Abstract
Topics: Thoracic Malignancies, Pathology/Molecular Biology

https://oncologypro.esmo.org/Meeting-Resour...pathological-features-in-lung-adenocarcinoma

BackgroundFRα is present on the cell surface, mediates its intracellular transport via receptor-mediated endocytosis, and is also involved in cell division. FRα is expressed at high levels on various...

Date: 05 Apr 2019
Presenter: Nobumasa Tamura
Resources: Abstract
Topics: Thoracic Malignancies, Pathology/Molecular Biology

https://oncologypro.esmo.org/Meeting-Resour...promotes-tumor-growth-in-lung-adenocarcinoma

BackgroundCircular RNAs (circRNA), a subclass of noncoding RNA characterized by covalently closed continuous loops, play emerging roles in tumorigenesis and aggressiveness.

Date: 05 Apr 2019
Presenter: Qi Huang
Resources: Abstract
Topic: Pathology/Molecular Biology

https://oncologypro.esmo.org/Meeting-Resour...-tissue-samples-of-patients-with-lung-cancer

BackgroundSomatic mutations of the gene encoding epidermal growth factor receptor (EGFR) are detected in approximately 30%–50% of patients with non-small cell lung cancers (NSCLC), so detection of...

Date: 05 Apr 2019
Presenter: Choonhee Son
Resources: Abstract
Topics: Thoracic Malignancies, Pathology/Molecular Biology

https://oncologypro.esmo.org/Meeting-Resour...ll-cell-lung-cancer-from-Chinese-populations

BackgroundAlthough roles of JAK2 mutations in myeloproliferative neoplasms (MPN) are well established, roles of JAK2 mutations in the pathogenesis of non-small cell lung cancer (NSCLC) remain unclear.

Date: 05 Apr 2019
Presenter: Wenxian Wang
Resources: Abstract
Topic: Pathology/Molecular Biology

https://oncologypro.esmo.org/Meeting-Resour...ations-in-Chinese-non-small-cell-lung-cancer

BackgroundVariation at TP63 has recently been shown to be associated with non-small cell lung cancer patients (NSCLC) in the Chinese population. There is some clinical evidence for the use of TP63...

Date: 05 Apr 2019
Presenter: Quxia Zhang
Resources: Abstract
Topic: Pathology/Molecular Biology

https://oncologypro.esmo.org/Meeting-Resour...ll-cell-lung-cancer-a-retrospective-analysis

BackgroundMET exon 14 skipping is a potential driver alteration in lung cancer targetable. Treatment with crizotinib can cause dramatic responses in patients whose cancers have MET exon 14 skipping.

Date: 05 Apr 2019
Presenter: Youcai Zhu
Resources: Abstract
Topic: Pathology/Molecular Biology